News Sentiment

HOWL sentiment intelligence

Werewolf Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 47 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.40 Week of 10 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+18.4% over one week, +5.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to earnings forward of Werewolf Therapeutics, Inc. – NASDAQ:HOWL

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 18.4% Price confirming higher
Trend fit Trend inactive 5.8% over four weeks
Fair value -81.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 23
Negative 15

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 7
Market source 5
Investing.com 5
TradingView 4
simplywall.st 3
Ad-hoc-news.de 2
Investing.com Nigeria 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 13
Deals and strategy 3
Balance sheet 2
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
TradingView Direct company coverage

Price to earnings forward of Werewolf Therapeutics, Inc. – NASDAQ:HOWL

This article provides a brief snapshot of the "Price to earnings forward" metric for Werewolf Therapeutics, Inc. (NASDAQ:HOWL) on TradingView. It shows the period, value, change, and percentage change. The content primarily focuses on the financial data point for the company.

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 04:39
Source
TradingView
MLQ.ai Direct company coverage

Werewolf Therapeutics, Inc. Net Debt / EBITDA (HOWL)

This article provides an analysis of Werewolf Therapeutics, Inc.'s Net Debt / EBITDA ratio, a key leverage metric. The company's Net Debt / EBITDA decreased significantly from 1.07 in FY2024 to 0.41 in FY2025, with a trailing-twelve-month figure of 0.26 as of Q1 FY26. The report

Tone
Neutral 50/100
Event
Balance sheet
Published
10 Jul 2026 06:16
Source
MLQ.ai
Ad-hoc-news.de Direct company coverage

HOWL stock stays in focus as Werewolf Therapeutics pursues immuno-oncology pipeline

Werewolf Therapeutics (HOWL) is a clinical-stage biotechnology company focused on developing novel immuno-oncology and immune-modulating therapies. The article discusses how HOWL stock reflects investor interest in the company's experimental pipeline, which targets cancer and aut

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 19:54
Source
Ad-hoc-news.de
Stock Titan Direct company coverage

Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares

Werewolf Therapeutics director Luke Evnin's associated funds sold a total of 143,199 shares of Common Stock in open-market transactions on July 6 and July 7, 2026. These sales, executed under a pre-established Rule 10b5-1 trading plan, resulted in a weighted average price of $0.3

Tone
Negative 31/100
Event
Market update
Published
09 Jul 2026 04:40
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com

This article announces the filing of a Form 4 for Werewolf Therapeutics Inc. on July 8, 2026, as reported by Investing.com. A Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of the company's stock. The article includes the stock sy

Tone
Positive 60/100
Event
Market update
Published
09 Jul 2026 04:11
Source
Investing.com Nigeria
Investing.com Direct company coverage

Werewolf Therapeutics director Luke Evnin sells $44,749 in stock

Luke Evnin, a director at Werewolf Therapeutics, Inc. (NASDAQ:HOWL), sold 143,199 shares of common stock for a total of $44,749 over two days, July 6 and July 7, 2026. The sales were executed through a Rule 10b5-1 trading plan at prices ranging from $0.31 to $0.32 per share. Desp

Tone
Negative 39/100
Event
Market update
Published
08 Jul 2026 22:40
Source
Investing.com
AD HOC NEWS Direct company coverage

Werewolf Therapeutics outlines its immuno-oncology strategy as Nasdaq-listed biotech

Werewolf Therapeutics (HOWL) is a clinical-stage biotech company listed on Nasdaq, focusing on immune-stimulating cancer therapies based on engineered cytokines. The company's strategy involves creating prodrugs that activate selectively in the tumor microenvironment to overcome

Tone
Positive 68/100
Event
Market update
Published
07 Jul 2026 17:11
Source
AD HOC NEWS
Stock Titan Direct company coverage

[144] Werewolf Therapeutics, Inc. SEC Filing

This article reports on a Form 144 SEC filing by Werewolf Therapeutics, Inc. (HOWL). The filing indicates a proposed sale of 21,194 shares of common stock with an aggregate market value of $7,214.44, acquired via a private placement in 2021. The article also provides details abou

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

RA Capital trims Werewolf Therapeutics (HOWL) stake below 5% threshold

RA Capital Management and its affiliated funds have reduced their stake in Werewolf Therapeutics (HOWL) to 4.1%, falling below the 5% beneficial ownership threshold. This change was reported in an Amendment No. 12 to their Schedule 13D filing, detailing open market sales between

Tone
Negative 40/100
Event
Deals and strategy
Published
03 Jul 2026 01:13
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 13D/A WEREWOLF THERAPEUTICS For: 2 July By Investing.com

Investing.com reports on a Form 13D/A filing for WEREWOLF THERAPEUTICS as of July 2nd. The article provides a brief mention of the filing along with updated market data and news headlines.

Tone
Negative 41/100
Event
Market update
Published
03 Jul 2026 00:13
Source
Investing.com Canada
MSN Direct company coverage

Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38

Werewolf Therapeutics (HOWL) has seen its price target increased by 20.19%, bringing it to $6.38. This adjustment indicates a more optimistic outlook for the company's stock from analysts.

Tone
Positive 72/100
Event
Guidance
Published
02 Jul 2026 06:10
Source
MSN
TradingView Direct company coverage

Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings

This article provides a comprehensive list of Werewolf Therapeutics, Inc.'s SEC filings and other financial documents, spanning from 2022 to 2026. It includes various earnings reports (10-K, 10-Q, 8-K), corporate event transcripts, and investor presentations, detailing the compan

Tone
Positive 63/100
Event
Earnings
Published
01 Jul 2026 18:40
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Werewolf Therapeutics Inc For: 29 June By Investing.com

This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Werewolf Therapeutics Inc (HOWL) related to June 29. It indicates insider transaction activity for the specified date. The piece also includes current stock market data for various indi

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 00:14
Source
Investing.com Nigeria
Investing.com Direct company coverage

Werewolf Therapeutics director Luke Evnin sells $47,125 in stock

Werewolf Therapeutics director Luke Evnin sold 157,084 shares of common stock for a total of $47,125 on June 29, 2026, at a weighted average price of $0.30 per share. The sale was executed through a Rule 10b5-1 trading plan and involved several entities. Following the transaction

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 23:41
Source
Investing.com
Stock Titan Direct company coverage

Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares

Entities associated with Werewolf Therapeutics director Luke Evnin sold 157,084 shares of HOWL common stock in an open-market transaction at a weighted average price of $0.30 per share. These sales were executed under a Rule 10b5-1 trading plan established on March 26, 2026. Afte

Tone
Negative 37/100
Event
Market update
Published
29 Jun 2026 22:41
Source
Stock Titan
TradingKey Direct company coverage

Werewolf Therapeutics Inc (HOWL) Financial Health: Profitability & Balance Sheet Analysis

Werewolf Therapeutics Inc (HOWL) has a current financial score of 6.80, placing it 206th out of 387 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The analysis highlights that relevant financial data for profitab

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 08:39
Source
TradingKey
Stock Titan Direct company coverage

RA Capital reports 6% Werewolf Therapeutics (HOWL) stake after June share sales

RA Capital Management and its associated funds have filed an amended Schedule 13D/A, disclosing a 6.0% beneficial ownership stake in Werewolf Therapeutics, Inc. (HOWL). This stake, totaling 2,915,742 shares, is held across RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fun

Tone
Negative 42/100
Event
Deals and strategy
Published
26 Jun 2026 22:09
Source
Stock Titan
Ad-hoc-news.de Direct company coverage

Werewolf Therapeutics details cancer pipeline progress, shares watched by biotech investors

Werewolf Therapeutics is advancing its conditionally activated cancer immunotherapies, specifically the WTX-124 and WTX-330 programs. The clinical-stage biotech aims to activate these INDUKINE molecules only in the tumor microenvironment to widen the therapeutic window for potent

Tone
Positive 71/100
Event
Market update
Published
26 Jun 2026 19:44
Source
Ad-hoc-news.de
Kavout | AI Direct company coverage

What's Behind the Recent Insider Selling at Werewolf Therapeutics (HOWL)

Director Luke Evnin recently sold over $66,000 worth of Werewolf Therapeutics (HOWL) stock through a pre-arranged Rule 10b5-1 plan, suggesting routine portfolio management rather than a direct bearish signal. However, significant net insider selling, coupled with the company's fi

Tone
Negative 40/100
Event
Market update
Published
26 Jun 2026 13:39
Source
Kavout | AI
TradingView Direct company coverage

Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL)

This article provides an overview of Werewolf Therapeutics, Inc. (NASDAQ: HOWL) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, such as upcoming earnings reports and past earnings per share, and addresses

Tone
Negative 38/100
Event
Earnings
Published
26 Jun 2026 11:39
Source
TradingView
Simply Wall Street Direct company coverage

Werewolf Therapeutics (Nasdaq:HOWL) - Stock Analysis

Werewolf Therapeutics (Nasdaq:HOWL) is a biopharmaceutical company focused on developing therapeutics to stimulate the immune system for cancer and immune-mediated conditions. The stock has experienced significant volatility and decline, with a current market cap of US$15.7m and

Tone
Negative 29/100
Event
Market update
Published
25 Jun 2026 12:10
Source
Simply Wall Street
Investing.com Canada Direct company coverage

Form 4 Werewolf Therapeutics Inc For: 22 June By Investing.com

This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Werewolf Therapeutics Inc (HOWL) dated June 22. Form 4 reports changes in beneficial ownership of company stock by insiders. The article contains minimal descriptive content beyond the

Tone
Neutral 50/100
Event
Regulatory and legal
Published
23 Jun 2026 22:09
Source
Investing.com Canada
Investing.com Direct company coverage

Ra Capital sells $145,918 of Werewolf Therapeutics (HOWL) stock

RA Capital, a major shareholder in Werewolf Therapeutics (NASDAQ:HOWL), sold 416,911 shares of common stock totaling $145,918 on June 17, 2026, at prices between $0.34 and $0.39 per share. These transactions were carried out indirectly by RA Capital Healthcare Fund, L.P. and RA C

Tone
Negative 29/100
Event
Market update
Published
22 Jun 2026 23:41
Source
Investing.com
Stock Titan Direct company coverage

[SCHEDULE 13D/A] Werewolf Therapeutics, Inc. Amended Major Shareholder Report

RA Capital Management and related entities have filed Amendment No. 10 to their Schedule 13D/A for Werewolf Therapeutics, Inc. (HOWL), updating their beneficial ownership to 7.5%, or 3,654,307 shares. This filing reports multiple open market sales by RA Capital Healthcare Fund, L

Tone
Negative 38/100
Event
Market update
Published
22 Jun 2026 23:41
Source
Stock Titan
Stock Titan Direct company coverage

RA Capital funds trim Werewolf Therapeutics (HOWL) stake with 416,911-share sale

Investment funds associated with RA Capital have sold 416,911 shares of Werewolf Therapeutics (HOWL) common stock in open-market transactions. The shares were sold at a weighted average price of $0.35, with individual trades ranging from $0.34 to $0.39. Following these sales, one

Tone
Negative 29/100
Event
Deals and strategy
Published
22 Jun 2026 22:41
Source
Stock Titan